“Perhaps” No Longer the Controlling Word
Until now, everything about Anavex Life Science Corp and it’s untested drugs was stated or regarded with words such as “Perhaps.”
“Perhaps Anavex 2-73 might yield some unique, helpful CNS disease outcomes. But no way to know yet.”
“Perhaps the molecule does, indeed, re-connect neuron organelles, allowing the restoration of normalized function. But not known with any certainty.”
“Perhaps Anavex 2-73 will be therapeutic for Alzheimer’s patients. But no way to know that without a proper, large-number double-blind clinical test.”
Now, statements about Anavex Life Sciences Corp and its drug Anavex 2-73 will no longer include the words “perhaps” or “maybe.”
The conduct of a large-scale, double-blind clinical trial, authorized and monitored by a modern nation’s medical control agency (in Australia) removes a lot of “maybe’s.” Anavex skeptics can express each of their previous cautions and warnings about the company and the drug’s insufficiencies and information gaps. But many of those are no longer valid.
A 48 week clinical trial, double-blind and placebo-controlled, is the gold standard of clinical drug trials. No one, pro or con, will be able to persuasively argue against whatever results appear from the trial.
The mere fact that Australian medical authorities have authorized and will monitor the trial is extremely affirmative. They don’t have any “concerns” or mis-givings about either the drug itself, nor the conduct of the new trial. They’ve given the go-ahead; pulling the air out of the so-often posted statements, here, of inadequacies of multiple kinds.
In short, Anavex Life Sciences Corp, and Anavex 2-73 are legitimate; not conjectural, “maybe” or “perhaps” entities any more. Anavex is now playing on the big stage, with a full script, with the best critics in the opening night audience. The program tells the unfolding story: The new drug Anavex 2-73 will be precisely tested on precisely selected Alzheimer’s patients who have the highest chances of gaining degrees of symptomatic relief. 450 actors, in three concurrent acts. On stage left, those getting a low dose of the drug. On center stage, actors getting a high dose. On stage right, those getting a starch pill that looks and tastes like the real pills the other actors are getting.
Come Thursday morning, who will be at the box office clamoring for tickets? Surely, a bunch of back of the house retail types; those who have been following the Anavex story, but awaiting “real news.” They have it, now.
But shoving their ways to the front of the lines will be investment fund managers, and higher-ups in pharmaceutical companies. Both will be greatly affected by how the play ends, how the plot turns out.
Will be fun watching how the investment and pharmaceutical press communities tell the new Anavex story. “Perhaps” will be replaced with “Will be closely watched....”
Most of us, here, have our tickets (well, AVXL shares). Will be one of the best stage shows in a long time.
